$CCCC
C4 Therapeutics, Inc. Stock $cccc

$cccc Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000162828023004711 Filed on February 23, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$3.759M	$2.854M	$31.10M
YoY Change	-50.89%	-85.79%	-32.08%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.95M	$10.50M	$42.79M
YoY Change	-14.63%	19.51%	28.67%
% of Gross Profit
Research & Development	$29.04M	$30.65M	$117.8M
YoY Change	10.83%	15.45%	24.48%
% of Gross Profit
Depreciation & Amortization	$500.0K	$521.0K	$1.676M
YoY Change	63.93%	61.3%	12.33%
% of Gross Profit
Operating Expenses	$39.99M	$41.15M	$160.6M
YoY Change	2.47%	16.45%	25.57%
Operating Profit	-$36.23M		-$129.5M
YoY Change	15.49%		57.71%
Interest Expense	$1.448M	$1.108M	$1.359M
YoY Change	-676.89%	-374.94%	-177.3%
% of Operating Profit
Other Income/Expense, Net	$1.448M		$1.359M
YoY Change	-676.89%		-177.3%
Pretax Income	-$34.78M	-$37.19M	-$128.2M
YoY Change	9.99%	137.48%	52.79%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$34.78M	-$37.19M	-$128.2M
YoY Change	9.99%	137.48%	52.79%
Net Earnings / Revenue	-925.25%	-1302.91%	-412.19%
Basic Earnings Per Share	-$0.71		-$2.62
Diluted Earnings Per Share	-$0.71	-$0.76	-$2.62
COMMON SHARES
Basic Shares Outstanding	49.05M shares	48.96M shares	48.86M shares
Diluted Shares Outstanding	49.03M shares		48.86M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$270.3M	$276.2M	$276.2M
YoY Change	-7.16%	-37.47%	-10.71%
Cash & Equivalents	$49.48M	$29.75M	$29.75M
Short-Term Investments	$220.8M	$246.4M	$246.4M
Other Short-Term Assets	$7.599M	$9.931M	$9.931M
YoY Change	-24.0%	-7.13%	-7.13%
Inventory
Prepaid Expenses
Receivables	$528.0K	$1.473M	$1.473M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$278.5M	$287.6M	$287.6M
YoY Change	-8.09%	-11.71%	-11.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.640M	$7.400M	$77.52M
YoY Change	152.48%	138.1%	121.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$34.71M	$60.96M	$60.96M
YoY Change	-73.4%	-57.13%	-57.13%
Other Assets	$3.360M	$1.526M	$4.805M
YoY Change	-20.13%	180.51%	25.69%
Total Long-Term Assets	$117.6M	$143.3M	$143.3M
YoY Change	-44.68%	-20.87%	-20.87%
TOTAL ASSETS
Total Short-Term Assets	$278.5M	$287.6M	$287.6M
Total Long-Term Assets	$117.6M	$143.3M	$143.3M
Total Assets	$396.0M	$430.8M	$430.8M
YoY Change	-23.17%	-14.98%	-14.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.034M	$1.172M	$1.172M
YoY Change	-69.63%	-73.99%	-73.99%
Accrued Expenses	$19.86M	$22.42M	$22.42M
YoY Change	76.44%	54.31%	54.31%
Deferred Revenue	$14.94M	$16.62M
YoY Change		-47.74%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.287M	$2.287M	$2.287M
YoY Change	204.93%
Total Short-Term Liabilities	$39.38M	$44.55M	$44.55M
YoY Change	-16.19%	-13.07%	-13.07%
LONG-TERM LIABILITIES
Long-Term Debt	$8.621M	$9.195M	$9.195M
YoY Change	-15.43%	-14.61%	-14.61%
Other Long-Term Liabilities	$85.57M	$87.87M	$87.87M
YoY Change	-8.75%	59.33%	59.33%
Total Long-Term Liabilities	$8.621M	$9.195M	$97.06M
YoY Change	-15.43%	-14.61%	47.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.38M	$44.55M	$44.55M
Total Long-Term Liabilities	$8.621M	$9.195M	$97.06M
Total Liabilities	$133.6M	$141.6M	$141.6M
YoY Change	-11.52%	20.87%	20.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$430.7M	-$395.9M
YoY Change	43.9%	47.88%
Common Stock	$695.6M	$689.3M
YoY Change		4.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$262.5M	$289.2M	$289.2M
YoY Change
Total Liabilities & Shareholders Equity	$396.0M	$430.8M	$430.8M
YoY Change	-23.17%	-14.98%	-14.98%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$34.78M	-$37.19M	-$128.2M
YoY Change	9.99%	137.48%	52.79%
Depreciation, Depletion And Amortization	$500.0K	$521.0K	$1.676M
YoY Change	63.93%	61.3%	12.33%
Cash From Operating Activities	-$33.13M	-$29.13M	-$105.9M
YoY Change	24.55%	13.47%	21.82%
INVESTING ACTIVITIES
Capital Expenditures	$589.0K	$1.490M	$5.496M
YoY Change	242.44%	-1466.97%	330.38%
Acquisitions
YoY Change
Other Investing Activities	$54.12M	$10.77M	$63.92M
YoY Change	-1512.32%	-118.17%	-133.99%
Cash From Investing Activities	$53.53M	$9.284M	$58.42M
YoY Change	-1436.94%	-115.63%	-130.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$684.0K	47.00K	$1.147M
YoY Change	-242.5%	-89.91%	-99.33%
NET CHANGE
Cash From Operating Activities	-$33.13M	-29.13M	-$105.9M
Cash From Investing Activities	$53.53M	9.284M	$58.42M
Cash From Financing Activities	-$684.0K	47.00K	$1.147M
Net Change In Cash	$19.72M	-19.80M	-$46.37M
YoY Change	-165.48%	-76.6%	-55.8%
FREE CASH FLOW
Cash From Operating Activities	-$33.13M	-$29.13M	-$105.9M
Capital Expenditures	$589.0K	$1.490M	$5.496M
Free Cash Flow	-$33.71M	-$30.62M	-$111.4M
YoY Change	25.95%	19.78%	26.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001662579
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#CollaborativeArrangementMember
CY2022	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#CollaborativeArrangementMember
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39567
CY2022	dei	Entity Registrant Name EntityRegistrantName	C4 Therapeutics, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5617627
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	490 Arsenal Way
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 120
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Watertown
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02472
CY2022	dei	City Area Code CityAreaCode	617
CY2022	dei	Local Phone Number LocalPhoneNumber	231-0700
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	CCCC
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	201260869	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49050851	shares
CY2022	dei	Auditor Firm AuditorFirmId	185
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, MA, United States
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29754000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76124000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	246399000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	233155000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1473000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5716000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9931000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10694000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	287557000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	325689000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	60962000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	142200000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7400000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3108000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	70116000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31945000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3279000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3279000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1526000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	544000	usd
CY2022Q4	us-gaap	Assets Assets	430840000	usd
CY2021Q4	us-gaap	Assets Assets	506765000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1172000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4506000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	19769000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13606000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16618000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	31800000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4700000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1334000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2287000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44546000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	51246000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16895000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	24368000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	70970000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30777000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9195000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	10768000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	141606000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	117159000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48966216	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48966216	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48688875	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48688875	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	689256000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	658091000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4137000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-775000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-395890000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-267715000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	289234000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	389606000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	430840000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	506765000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31096000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45785000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	117841000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	94665000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42789000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33254000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	160630000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	127919000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-129534000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-82134000	usd
CY2022	cccc	Interest Expense And Amortization Long Term Debt Related Party InterestExpenseAndAmortizationLongTermDebtRelatedParty	2216000	usd
CY2021	cccc	Interest Expense And Amortization Long Term Debt Related Party InterestExpenseAndAmortizationLongTermDebtRelatedParty	2145000	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	3575000	usd
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	387000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1359000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1758000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-128175000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83892000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.62
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.62
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.82
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.82
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48861665	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48861665	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46041733	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46041733	shares
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3362000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-788000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-131537000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84680000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	280791000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	11300000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	169465000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2330000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	180000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21340000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-788000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83892000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	180000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	389606000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	777000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	372000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29858000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3362000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-128175000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	158000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	289234000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-128175000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83892000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	30016000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	21512000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1676000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1492000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	5896000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1415000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-714000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1879000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	713000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	719000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4244000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1232000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-388000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6116000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3333000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1179000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5083000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4377000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-507000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-888000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-22654000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-25052000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-105939000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-86965000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	283445000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	349681000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	219527000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	537740000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5496000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1277000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	58422000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-189336000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	11300000	usd
CY2022	cccc	Proceeds From Issuance Of Follow On Offering ProceedsFromIssuanceOfFollowOnOffering	0	usd
CY2021	cccc	Proceeds From Issuance Of Follow On Offering ProceedsFromIssuanceOfFollowOnOffering	169465000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	777000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2330000	usd
CY2022	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0	usd
CY2021	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	286000	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	370000	usd
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-109000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1147000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	171400000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-46370000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-104901000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	79403000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184304000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33033000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	79403000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33033000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	79403000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3279000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3279000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29754000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76124000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1624000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1308000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	44067000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	20131000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	473000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022	cccc	Aggregate Exercise Price Of Warrant Net Exercised Related Party AggregateExercisePriceOfWarrantNetExercisedRelatedParty	0	usd
CY2021	cccc	Aggregate Exercise Price Of Warrant Net Exercised Related Party AggregateExercisePriceOfWarrantNetExercisedRelatedParty	3002000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-128200000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83900000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-395900000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	337100000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements if these results differ from historical experience or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, amounts and timing of revenues recognized under the Company’s research and development collaboration arrangements, prepaid and accrued research and development expense, incremental borrowing rate used in the measurement of lease liability, and estimated volatility used in our valuation of stock-based awards. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. Additionally, the Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.</span></div>
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	336865000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	451166000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	311498000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4141000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	307361000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	376130000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	776000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	375355000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	120	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	289434000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	4141000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	123	security
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	365505000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	776000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	security
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15523000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10024000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8123000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6916000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7400000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3108000	usd
CY2022	us-gaap	Depreciation Depreciation	1676000	usd
CY2021	us-gaap	Depreciation Depreciation	1492000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	10031000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2686000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	2026000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	857000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	1481000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2022	us-gaap	Lease Cost LeaseCost	10576000	usd
CY2021	us-gaap	Lease Cost LeaseCost	3543000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8571000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8828000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	9093000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	9366000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	9646000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	52113000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	97617000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	21947000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	75670000	usd
CY2022Q4	cccc	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	9824000	usd
CY2021Q4	cccc	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	6863000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	6831000	usd
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5084000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1062000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1246000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2052000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	413000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	19769000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13606000	usd
CY2022Q4	cccc	Transaction Price Allocated To Performance Obligation TransactionPriceAllocatedToPerformanceObligation	67822000	usd
CY2022Q4	cccc	Transaction Price Unsatisfied To Performance Obligation TransactionPriceUnsatisfiedToPerformanceObligation	28044000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31096000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45785000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1473000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16618000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16895000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	33513000	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	5716000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	31800000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	24368000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	56168000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	25412000	usd
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	34363000	usd
CY2022	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	518000	usd
CY2021	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	1654000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	3000000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9500000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	12500000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1018000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	11482000	usd
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022	cccc	Common Stock Number Of Votes Each Share CommonStockNumberOfVotesEachShare	1	vote
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30016000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21512000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.080
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.060
CY2022	cccc	Effective Income Tax Rate Reconciliation Federal Tax Credit EffectiveIncomeTaxRateReconciliationFederalTaxCredit	0.014
CY2021	cccc	Effective Income Tax Rate Reconciliation Federal Tax Credit EffectiveIncomeTaxRateReconciliationFederalTaxCredit	0.031
CY2022	cccc	Effective Income Tax Rate Reconciliation State Tax Credit EffectiveIncomeTaxRateReconciliationStateTaxCredit	0.001
CY2021	cccc	Effective Income Tax Rate Reconciliation State Tax Credit EffectiveIncomeTaxRateReconciliationStateTaxCredit	0.017
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.008
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.030
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.013
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.267
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.302
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	54300000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	46339000	usd
CY2022Q4	cccc	Deferred Tax Assets Capitalized Research And Development Expenditures DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures	27568000	usd
CY2021Q4	cccc	Deferred Tax Assets Capitalized Research And Development Expenditures DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures	0	usd
CY2022Q4	cccc	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	21443000	usd
CY2021Q4	cccc	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	9290000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	11519000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9560000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	8457000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	15053000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6296000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3675000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	1090000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	195000	usd
CY2022Q4	cccc	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	699000	usd
CY2021Q4	cccc	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	875000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	354000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	426000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	131726000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	85413000	usd
CY2022Q4	cccc	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	19868000	usd
CY2021Q4	cccc	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	9242000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1738000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	725000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	110120000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	75446000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	110100000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	75400000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	34700000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	25600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	171600000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	152200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	171600000	usd
CY2022	cccc	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Percent EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActPercent	0.80
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	273600000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	216800000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-128175000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83892000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48861665	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48861665	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46041733	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46041733	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.62
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.62
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.82
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.82
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.90
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	1
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1000000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
cccc-20221231_lab.xml	Edgar Link	unprocessable
0001628280-23-004711-index-headers.html	Edgar Link	pending
0001628280-23-004711-index.html	Edgar Link	pending
0001628280-23-004711.txt	Edgar Link	pending
0001628280-23-004711-xbrl.zip	Edgar Link	pending
cccc-20211231x10kex311.htm	Edgar Link	pending
cccc-20211231x10kex312.htm	Edgar Link	pending
cccc-20211231x10kex321.htm	Edgar Link	pending
cccc-20211231x10kex322.htm	Edgar Link	pending
cccc-20221231.htm	Edgar Link	pending
cccc-20221231.xsd	Edgar Link	pending
cccc-20221231_g1.jpg	Edgar Link	pending
cccc-20221231_g10.jpg	Edgar Link	pending
cccc-20221231_g11.jpg	Edgar Link	pending
cccc-20221231_g12.jpg	Edgar Link	pending
cccc-20221231_g13.jpg	Edgar Link	pending
cccc-20221231_g14.jpg	Edgar Link	pending
cccc-20221231_g15.jpg	Edgar Link	pending
cccc-20221231_cal.xml	Edgar Link	unprocessable
cccc-20221231_def.xml	Edgar Link	unprocessable
cccc-20221231_g16.jpg	Edgar Link	pending
cccc-20221231_g17.jpg	Edgar Link	pending
cccc-20221231_g18.jpg	Edgar Link	pending
cccc-20221231_g19.jpg	Edgar Link	pending
cccc-20221231_g2.jpg	Edgar Link	pending
cccc-20221231_g20.jpg	Edgar Link	pending
cccc-20221231_g21.jpg	Edgar Link	pending
cccc-20221231_g22.jpg	Edgar Link	pending
cccc-20221231_g23.jpg	Edgar Link	pending
cccc-20221231_g3.jpg	Edgar Link	pending
cccc-20221231_g4.jpg	Edgar Link	pending
cccc-20221231_g5.jpg	Edgar Link	pending
cccc-20221231_g6.jpg	Edgar Link	pending
cccc-20221231_g7.jpg	Edgar Link	pending
cccc-20221231_g8.jpg	Edgar Link	pending
cccc-20221231_g9.jpg	Edgar Link	pending
exhibit102.htm	Edgar Link	pending
exhibit211.htm	Edgar Link	pending
exhibit231.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
cccc-20221231_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cccc-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CCCC
C4 Therapeutics, Inc. Stock $cccc

2023 Q1 Form 10-K Financial Statement

#000162828023004711 Filed on February 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CCCC C4 Therapeutics, Inc. Stock $cccc

2023 Q1 Form 10-K Financial Statement

#000162828023004711 Filed on February 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CCCC
C4 Therapeutics, Inc. Stock $cccc